Clinical Trial Update: High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI [Phase 2]

View source ↗

Summary

Phase 2 trial of high-dose interleukin-2 combined with recMAGE-A3 + AS15 for melanoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• High-dose interleukin-2 (interleukin-2)
• recMAGE-A3 + AS15 (recMAGE-A3)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2020-02-19